Moneycontrol PRO
Loans
Loans
HomeNewsIndiaIndia reports 163 cases of new Covid-19 variant XFG: Is it a cause for concern?

India reports 163 cases of new Covid-19 variant XFG: Is it a cause for concern?

India Covid-19 latest news: India's active COVID case tally crossed the 6,000 mark, with 769 added in the last 48 hours, according to the Union health ministry data released on Sunday.

June 09, 2025 / 20:50 IST

A newly identified COVID-19 variant, known as XFG, has been detected in 163 cases across India, according to the latest bulletin released by INSACOG – the Indian SARS-CoV-2 Genomics Consortium.

According to data from INSACOG, the XFG variant of the COVID-19-causing virus has been found in a total of 163 samples – highest (89) in Maharashtra, followed by Tamil Nadu (16), Kerala (15), Gujarat (11), and Andhra Pradesh, Madhya Pradesh and West Bengal (six each).

In May, as many as 159 samples were detected with XFG variant while two samples tested for this variant in April and two in June yet, data shows.

India's active COVID case tally crossed the 6,000 mark, with 769 added in the last 48 hours, according to the Union health ministry data released on Sunday.

What is the XFG variant?

The XFG variant is classified as a recombinant sub-lineage, which means it likely emerged as a result of genetic recombination between two previously circulating Omicron sub-variants. Recombinant variants are not new in the pandemic's trajectory – strains like XBB, XE, and XBF were also recombinants of earlier Omicron branches.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

XFG contains a mixture of genetic material from these prior variants, but virologists caution that recombinants aren’t inherently more dangerous — their threat level depends on how transmissible they are and whether they can evade existing immunity.

So far, XFG has not been designated as a Variant of Concern (VOC) or Variant of Interest (VOI) by either the World Health Organisation (WHO) or India’s Ministry of Health. This means that, for now, it is not linked with major outbreaks, spikes in hospitalisations, or vaccine resistance.

Is XFG more dangerous?

At this stage, there is no evidence that XFG causes more severe illness or leads to higher mortality compared to other Omicron sub-variants. Like most Omicron-descendant strains, it appears to be associated with mild upper respiratory symptoms in most vaccinated or previously infected individuals.

However, health officials stress that the evolution of the virus remains unpredictable. Variants with immune-evasive characteristics or mutations that enhance their binding to human cells (via the spike protein) could cause new waves if left unchecked.

Indian scientists are monitoring the XFG variant due to key spike protein mutations—His445Arg, Asn487Asp, Gln493Glu, and Thr572Ile—that could impact the virus’s ability to infect cells, dodge immunity, and spread more quickly, according to The Lancet.

Some mutations weaken the virus’s ability to bind to human cells—known as reduced ACE2 receptor binding—while others help it evade the immune system, allowing it to slip past the body’s natural defences or vaccine protection.

Are vaccine effective against XFG?

India’s current Covid-19 vaccines – including Covaxin, Covishield, and newer booster doses – are still expected to offer protection against serious illness and hospitalization from the XFG variant. While mild breakthrough infections are possible, particularly as antibodies wane over time, the T-cell immunity provided by vaccines is likely to remain effective.

Moneycontrol News
first published: Jun 9, 2025 08:50 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347